These findings have been therapeutically exploited, showing that M-CSFR inhibition via small molecule inhibitors or blocking antibodies decreases the presence of TAM in transplantable or spontaneous tumor models and leads to a reduced tumor angiogenesis and lymphangiogenesis (100–102). Here, CSF1R is linked to neoplasm.